Bepreve (Bepotastine Besilate) Patent Expiration, LOE Window & CMS Spending

Bepreve (Bepotastine Besilate) by Bausch Health: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $2.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN022288 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.